FIREBRICKPHARMA ORDINARY (FRE) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXNasodine Composition Patent Granted in New Zealand
other announcement
Change of Director's Interest Notice - Peter Molloy
director_dealing announcement
Change of Director's Interest Notice - Stephen Goodall
director_dealing announcement
March 2026 Quarterly Activity Report & Appendix 4C
other announcement
Firebrick Secures $1.5 million via Placement
capital_raise announcement
Registration Agreement and Approval of Nasodine in Indonesia
other announcement
Firebrick to present at NWR Virtual Healthcare Conference
other announcement
FRE appoints Head of Business Development and Licensing
other announcement
Appendix 4D & Half-Year Financial Report to 31 December 2025
other announcement
December 2025 Quarterly Activity Report & Appendix 4C
other announcement
Update on Registration of Nasodine in the Philippines
other announcement
Firebrick announces new product Nasodine Throat Spray
other announcement
Notice of AGM & Proxy Form & Letter to Shareholders
other announcement
September 2025 Quarterly Activity Report & Appendix 4C
other announcement
Becoming a substantial holder - Pharma Nutria NA Inc
other announcement